+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Obesity Drugs Market by Product Type, Distribution Channel, End User, Dosage Form - Global Forecast to 2030- Product Image
Anti-Obesity Drugs Market by Product Type, Distribution Channel, End User, Dosage Form - Global Forecast to 2030- Product Image
Sale

Anti-Obesity Drugs Market by Product Type, Distribution Channel, End User, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5317899
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-obesity drugs market is advancing rapidly, spurred by groundbreaking developments and a growing focus on innovative treatments. As obesity rates rise globally, this market is experiencing transformative changes driven by scientific breakthroughs, policy shifts, and increasing public health initiatives. Recent growth from USD 4.09 billion in 2024 to USD 4.38 billion in 2025, with an expected reach of USD 6.11 billion by 2030, highlights the momentum of this dynamic sector.

Setting the Stage for an Evolving Anti-Obesity Market

The market is at a pivotal juncture, marked by advances in peptide-based therapies that redefine treatment paradigms with unprecedented efficacy and safety. This innovation coincides with increased public awareness and strategic partnerships rekindling traditional drug development and patient engagement models. The integration of digital health solutions complements pharmacotherapy, creating a comprehensive approach to weight management.

Dynamic Forces Reshaping the Anti-Obesity Drug Landscape

Next-generation therapies, such as GLP-1 agonists, are at the forefront, achieving results comparable to bariatric surgery. This breakthrough leads to explorations of dual- and triple-agonist molecules targeting additional metabolic pathways. The rise of digital therapeutics and remote monitoring enhances patient engagement, while value-based reimbursement schemes pilot new ways of incentivizing healthcare providers.

Deep Dive into Market Segmentation and Patient Pathways

The market is categorized by product type, with GLP-1 agonists as leading contenders due to their effective weight reduction capabilities. Oral formulations like Naltrexone Bupropion and Phentermine Topiramate retain niche positions, while Orlistat and SGLT2 inhibitors serve specific metabolic profiles. Distribution channels, including hospital and retail pharmacies, play vital roles in market access, with evolving end-user preferences towards injectables and tablets.

Regional Dynamics Driving Anti-Obesity Drug Opportunities

Regional factors significantly impact the uptake and reimbursement of anti-obesity treatments. The Americas lead with robust frameworks accelerating access to premium therapies. Europe, Middle East & Africa present varied challenges and opportunities, with Asia-Pacific exhibiting rapid growth driven by expanding health programs and private investment.

Strategic Profiles of Leading Anti-Obesity Drug Developers

Leading companies excel through differentiated pipelines and strategic partnerships, advancing therapies like semaglutide and dual-agonist candidates. Collaborations with digital health ventures enable comprehensive care platforms, while biotech firms position themselves as agile innovators in the competitive landscape.

Actionable Strategies to Propel Market Leadership

To thrive, industry leaders should balance pipeline innovation with agile market strategies, invest in next-generation agonists, and secure value-based contracts. Strengthening supply chain resilience and integrating digital health solutions will enhance patient engagement, driving growth and reinforcing competitive advantages.

Assessing the 2025 United States Tariff Effects on Anti-Obesity Therapies

New tariffs on pharmaceutical APIs will impact supply chains and cost structures. Manufacturers are deploying mitigation tactics, including dual-sourcing and domestic production, to counteract potential supply disruptions. These strategies aim to maintain product affordability and ensure stable patient access.

Key Takeaways from This Report

  • Advances in GLP-1 agonists position them as a cornerstone in anti-obesity treatments.
  • Digital health integration enhances patient engagement and supports pharmacotherapy outcomes.
  • Strategic partnerships and regional dynamics create a diverse landscape for growth and investment.

Strategic alignment with these insights will aid stakeholders in navigating challenges and capitalizing on opportunities for sustainable market leadership.

Robust Framework Underpinning Our Research Approach

This analysis is based on a rigorous research process, involving comprehensive desk research, expert interviews, and data triangulation. Quantitative surveys provided statistical validation of projections, ensuring that the findings are actionable and relevant for strategic decision-making.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising burden of obesity and related chronic diseases
5.1.1.2. Rapid consumption of unhealthy fast-foods and ready meals
5.1.1.3. Increasing inclination towards health & fitness
5.1.2. Restraints
5.1.2.1. Side-effects associated with drugs
5.1.3. Opportunities
5.1.3.1. Growing awareness among people with collaborative strategies
5.1.3.2. Recent advancements in drug treatment of obesity
5.1.4. Challenges
5.1.4.1. Availability of alternative treatment options in market
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Anti-Obesity Drugs Market, by Drug Type
6.1. Introduction
6.2. Over-The-Counter Drugs
6.3. Prescription Drugs
7. Anti-Obesity Drugs Market, by Mechanism of Action
7.1. Introduction
7.2. Centrally Acting Drugs
7.3. Peripherally Acting Drugs
8. Americas Anti-Obesity Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Anti-Obesity Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Anti-Obesity Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTI-OBESITY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTI-OBESITY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTI-OBESITY DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CENTRALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PERIPHERALLY ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 18. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 20. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 21. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 22. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 23. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 32. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 34. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 36. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 38. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 40. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 42. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 46. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 48. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 52. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. DENMARK ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 59. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. EGYPT ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 61. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 62. FINLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 63. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 64. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 67. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 69. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 71. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 75. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. NORWAY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. POLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 88. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 91. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. TURKEY ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 100. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The companies profiled in this Anti-Obesity Drugs market report include:
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Pfizer Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Sanofi S.A.
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Zealand Pharma A/S

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.38 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.11 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players - Product Image

Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players

  • Report
  • 240 Pages
  • Global
From
North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029 - Product Image

North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023-2029

  • Report
  • 72 Pages
  • North America
From
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032 - Product Image

Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Asia Pacific
From
Anti-Obesity Drugs - Global Strategic Business Report - Product Image

Anti-Obesity Drugs - Global Strategic Business Report

  • Report
  • 264 Pages
  • Global
From
Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.